Yield10 Bioscience Inc (YTEN.OQ)

YTEN.OQ on NASDAQ Stock Exchange Capital Market

17 Nov 2017
Change (% chg)

$-0.08 (-2.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Yield10 Bioscience posts Q3 loss $0.59/shr from continuing operations
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Yield10 Bioscience Inc :Yield10 Bioscience announces third quarter 2017 financial results.Q3 loss per share $0.59 from continuing operations.Q3 revenue $200,000 versus $500,000.Yield10 Bioscience Inc - expects to use about $8.0 million to $8.5 million in cash for FY 2017, including anticipated payments for restructuring costs​.Yield10 Bioscience Inc - expects current cash resources will be sufficient to fund operations & meet obligations into Q1 2018​.Yield10 - "the ‍company's present capital resources raise substantial doubt, however, about company's ability to continue as a going concern"​.  Full Article

Metabolix announces $10 mln binding letter of intent for sale of biopolymer assets
Tuesday, 23 Aug 2016 

Metabolix Inc : Announces $10 million binding letter of intent for sale of biopolymer assets to CJ CheilJedang . First $2 million of purchase price was paid by CJ on execution of LOI . Remaining balance on purchase price is payable on closing of transaction, which is anticipated in mid-September . Will transfer to CJ portfolio of intellectual property including platform microbial strains used to produce co's fermentation based products . Metabolix sees annual net cash burn rate in range of $5 million once it has completed "transition and related restructuring" .CJ will also acquire certain laboratory equipment associated with biopolymers business from co.  Full Article

Metabolix estimates restructuring charges of approx $4 mln during Q3
Wednesday, 27 Jul 2016 

Metabolix Inc : Also expects to record a non-cash impairment charge of approximately $0.6 million during its q3 .Estimates that it will record restructuring charges of approximately $4.0 million during its third fiscal quarter of 2016.  Full Article

Metabolix announces strategic restructuring
Friday, 22 Jul 2016 

Metabolix Inc : As part of restructuring, Metabolix will eliminate approximately 45 positions in its biopolymer operations and corporate organization, . Metabolix announces new strategic direction: Yield10 Bioscience to become core business, biopolymers operations to be wound down . As part of restructuring, will pursue sale of its biopolymers business assets .Consistent with its new strategy, company plans to rebrand itself as Yield10 Bioscience in coming months..  Full Article

Metabolix had unrestricted cash and cash equivalents of about $5.3 mln as of March 31 - SEC Filing
Friday, 8 Jul 2016 

Metabolix Inc: As of March 31, 2016, company had unrestricted cash and cash equivalents of approximately $5.3 million . "We are continuing to explore both equity and debt financing as well as other opportunities to selectively monetize assets" - SEC Filing . If not able to secure capital resource fund for strategic review process, operations, will be forced to wind down some/all of operations .Capital resources insufficient to fund operations for 12-month period, raise doubt about ability to continue as a going concern.  Full Article

Metabolix files for secondary offering of upto 5.4 million shares
Wednesday, 8 Jun 2016 

Metabolix Inc : Metabolix Inc Files For Secondary Offering Of Upto 5.4 Million Shares Of Common Stock By Selling Shareholders - Sec Filing Source (http://bit.ly/25MAgYJ) Further company coverage: [MBLX.O] ((Bengaluru Newsroom; +1 646 223 8780;)).  Full Article

Metabolix says amends license agreement with Tepha
Friday, 20 May 2016 

Metabolix Inc : On May 17, 2016, Metabolix Inc entered into an amendment to its license agreement with Tepha Inc - SEC filing . Under amendment Tepha made a $2 million sum payment to Metabolix . In exchange for payment, Metabolix agreed to forgo future royalties under its existing license agreements with Tepha . Metabolix also agreed to provide two additional Metabolix production strains to Tepha .Also agreed granted Tepha a royalty-free license to related intellectual property for use in production of Tepha's medical devices.  Full Article